Tirzepatide weight loss research: SURMOUNT trial data, dual agonism mechanisms, and research protocol guide.
Why Tirzepatide Outperforms GLP-1 Alone
The SURMOUNT program is the most comprehensive obesity trial program ever conducted for a single agent, enrolling over 5,000 participants across five pivotal trials. Results below are from the primary endpoints at 72 weeks (SURMOUNT-1/2) and 52 weeks
SURMOUNT Trial Weight Loss Results by Dose
Most patients experience a weight loss plateau around weeks 24–36. This is a normal physiological response — as body weight decreases, basal metabolic rate decreases proportionally, reducing the caloric deficit created by tirzepatide's appetite suppr
Tirzepatide Dosage by Weight Loss Goal
The SURMOUNT program is the most comprehensive obesity trial program ever conducted for a single agent, enrolling over 5,000 participants across five pivotal trials. Results below are from the primary endpoints at 72 weeks (SURMOUNT-1/2) and 52 weeks